3 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
| 1 | 33941543 | Nonclinical Pharmacokinetics and Absorption, Distribution, Metabolism, and Excretion of Givosiran, the First Approved N-Acetylgalactosamine-Conjugated RNA Interference Therapeutic. | 2021 Jul | 2 |
| 2 | 31792921 | Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. | 2020 Feb | 1 |
| 3 | 26528940 | Preclinical Development of a Subcutaneous ALAS1 RNAi Therapeutic for Treatment of Hepatic Porphyrias Using Circulating RNA Quantification. | 2015 Nov 3 | 1 |